Advertisement

Use and Impact of Type 2 Diabetes Prevention Interventions

      Introduction

      RCTs have found that type 2 diabetes can be prevented among high-risk individuals by metformin medication and evidence-based lifestyle change programs. The purpose of this study is to estimate the use of interventions to prevent type 2 diabetes in real-world clinical practice settings and determine the impact on diabetes-related clinical outcomes.

      Methods

      The analysis performed in 2020 used 2010‒2018 electronic health record data from 69,434 patients aged ≥18 years at high risk for type 2 diabetes in 2 health systems. The use and impact of prescribed metformin, lifestyle change program, bariatric surgery, and combinations of the 3 were examined. A subanalysis was performed to examine uptake and retention among patients referred to the National Diabetes Prevention Program.

      Results

      Mean HbA1c values declined from before to after intervention for patients who were prescribed metformin (−0.067%; p<0.001) or had bariatric surgery (−0.318%; p<0.001). Among patients referred to the National Diabetes Prevention Program lifestyle change program, the type 2 diabetes postintervention incidence proportion was 14.0% for nonattendees, 12.8% for some attendance, and 7.5% for those who attended ≥4 sessions (p<0.001). Among referred patients to the National Diabetes Prevention Program lifestyle change program, uptake was low (13% for 1‒3 sessions, 15% for ≥4 sessions), especially among males and Hispanic patients.

      Conclusions

      Findings suggest that metformin and bariatric surgery may improve HbA1c levels and that participation in the National Diabetes Prevention Program may reduce type 2 diabetes incidence. Efforts to increase the use of these interventions may have positive impacts on diabetes-related health outcomes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Centers for Disease Control and Prevention
        National diabetes statistics report.
        Centers for Disease Control and Prevention, HHS, Atlanta, GA2020 (PublishedAccessed September 6, 2021)
        • Tabák AG
        • Herder C
        • Rathmann W
        • Brunner EJ
        • Kivimäki M.
        Prediabetes: a high-risk state for diabetes development.
        Lancet. 2012; 379: 2279-2290https://doi.org/10.1016/S0140-6736(12)60283-9
        • Cunningham SA
        • Patel SA
        • Beckles GL
        • et al.
        County-level contextual factors associated with diabetes incidence in the United States.
        Ann Epidemiol. 2018; 28 (e2): 20-25https://doi.org/10.1016/j.annepidem.2017.11.002
        • Schwartz BS
        • Pollak J
        • Poulsen MN
        • et al.
        Association of community types and features in a case-control analysis of new onset type 2 diabetes across a diverse geography in Pennsylvania.
        BMJ Open. 2021; 11e043528https://doi.org/10.1136/bmjopen-2020-043528
        • Knowler WC
        • Barrett-Connor E
        • Fowler SE
        • et al.
        Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
        N Engl J Med. 2002; 346: 393-403https://doi.org/10.1056/NEJMoa012512
        • Courcoulas AP
        • Yanovski SZ
        • Bonds D
        • et al.
        Long-term outcomes of bariatric surgery: a National Institutes of Health Symposium.
        JAMA Surg. 2014; 149: 1323-1329https://doi.org/10.1001/jamasurg.2014.2440
        • Lindström J
        • Ilanne-Parikka P
        • Peltonen M
        • et al.
        Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
        Lancet. 2006; 368: 1673-1679https://doi.org/10.1016/S0140-6736(06)69701-8
        • Grams J
        • Garvey WT.
        Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action.
        Curr Obes Rep. 2015; 4: 287-302https://doi.org/10.1007/s13679-015-0155-x
        • American Diabetes Association
        5. Prevention or delay of type 2 diabetes: standards of Medical Care in Diabetes-2018.
        Diabetes Care. 2018; 41: S51-S54https://doi.org/10.2337/dc18-S005
        • Hostalek U
        • Gwilt M
        • Hildemann S.
        Therapeutic use of metformin in prediabetes and diabetes prevention.
        Drugs. 2015; 75: 1071-1094https://doi.org/10.1007/s40265-015-0416-8
        • Venkataramani M
        • Pollack CE
        • Yeh HC
        • Maruthur NM.
        Prevalence and correlates of diabetes prevention program referral and participation.
        Am J Prev Med. 2019; 56: 452-457https://doi.org/10.1016/j.amepre.2018.10.005
        • Ali MK
        • McKeever Bullard K
        • Imperatore G
        • et al.
        Reach and use of diabetes prevention services in the United States, 2016-2017.
        JAMA Netw Open. 2019; 2e193160https://doi.org/10.1001/jamanetworkopen.2019.3160
        • Zhou X
        • Siegel KR
        • Ng BP
        • et al.
        Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: a systematic review.
        Diabetes Care. 2020; 43: 1593-1616https://doi.org/10.2337/dci20-0018
        • Diabetes Prevention Program Research Group
        Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
        Lancet Diabetes Endocrinol. 2015; 3: 866-875https://doi.org/10.1016/S2213-8587(15)00291-0
      1. Report to congress on leveraging federal programs to prevent and control diabetes and its complications. National Clinical Care Commission. https://health.gov/about-odphp/committees-workgroups/national-clinical-care-commission/report-congress. Updated March 22, 2022. Accessed January 23, 2022.

        • Gregg EW
        • Duru OK
        • Shi L
        • et al.
        Filling the public health science gaps for diabetes with natural experiments.
        Med Care. 2020; 58: S1-S3https://doi.org/10.1097/MLR.0000000000001330
        • Moin T
        • Schmittdiel JA
        • Flory JH
        • et al.
        Review of metformin use for type 2 diabetes prevention.
        Am J Prev Med. 2018; 55: 565-574https://doi.org/10.1016/j.amepre.2018.04.038
      2. The National Diabetes Prevention Program (National DPP) lifestyle change program.
        Centers for Disease Control and Prevention (CDC), 2021 (https://coveragetoolkit.org/about-national-dpp/. Updated June 16, 2021)
        • Cannon MJ
        • Masalovich S
        • Ng BP
        • et al.
        Retention among participants in the National Diabetes Prevention Program lifestyle change program, 2012‒2017.
        Diabetes Care. 2020; 43: 2042-2049https://doi.org/10.2337/dc19-2366
        • Fishbein HA
        • Birch RJ
        • Mathew SM
        • et al.
        The Longitudinal Epidemiologic Assessment of Diabetes Risk (LEADR): unique 1.4 M patient electronic health record cohort.
        Healthc (Amst). 2020; 8100458https://doi.org/10.1016/j.hjdsi.2020.100458
        • Centers for Disease Control and Prevention
        National diabetes prevention program: prediabetes risk test.
        Centers for Disease Control and Prevention, Atlanta, GA2021 (https://www.cdc.gov/diabetes/prevention/pdf/Prediabetes-Risk-Test-Final.pdf. Accessed May 16, 2022)
        • Geospatial research, analysis, and services program
        CDC Social Vulnerability Index 2014 United States database.
        Centers for Disease Control and Prevention, Agency for Toxic Substances and Disease Registry, 2021 (Updated August 27Accessed September 6, 2021)
        • Deyo RA
        • Cherkin DC
        • Ciol MA.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619https://doi.org/10.1016/0895-4356(92)90133-8
        • Ritchie ND
        • Christoe-Frazier L
        • McFann KK
        • Havranek EP
        • Pereira RI.
        Effect of the National Diabetes Prevention Program on weight loss for English- and Spanish-speaking Latinos.
        Am J Health Promot. 2018; 32: 812-815https://doi.org/10.1177/0890117117698623
        • Ritchie ND.
        Solving the puzzle to lasting impact of the National Diabetes Prevention Program.
        Diabetes Care. 2020; 43: 1994-1996https://doi.org/10.2337/dci20-0031
        • Cefalu WT
        • Buse JB
        • Tuomilehto J
        • et al.
        Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a Diabetes Care editors’ expert forum.
        Diabetes Care. 2016; 39: 1186-1201https://doi.org/10.2337/dc16-0873
        • Perreault L
        • Pan Q
        • Mather KJ
        • Watson KE
        • Hamman RF
        • Kahn SE.
        Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
        Lancet. 2012; 379: 2243-2251https://doi.org/10.1016/S0140-6736(12)60525-X
        • Gruss SM
        • Nhim K
        • Gregg E
        • Bell M
        • Luman E
        • Albright A
        Public health approaches to type 2 diabetes prevention: the U.S. National Diabetes Prevention Program and beyond [published correction appears in Curr Diab Rep. 2020;20(8):36].
        Curr Diab Rep. 2019; 19: 78https://doi.org/10.1007/s11892-020-01323-x
        • Burd C
        • Gruss S
        • Albright A
        • Zina A
        • Schumacher P
        • Alley D.
        Translating knowledge into action to prevent type 2 diabetes: Medicare expansion of the National Diabetes Prevention Program Lifestyle Intervention.
        Milbank Q. 2020; 98: 172-196https://doi.org/10.1111/1468-0009.12443
        • Ritchie ND
        • Phimphasone-Brady P
        • Sauder KA
        • Amura CR.
        Perceived barriers and potential solutions to engagement in the National Diabetes Prevention Program.
        ADCES Pract. 2021; 9: 16-20https://doi.org/10.1177/2633559X20966275
        • Ritchie ND
        • Kaufmann PG
        • Gritz RM
        • Sauder KA
        • Holtrop JS.
        Presessions to the National Diabetes Prevention Program may be a promising strategy to improve attendance and weight loss outcomes.
        Am J Health Promot. 2019; 33: 289-292https://doi.org/10.1177/0890117118786195
        • Ritchie ND
        • Baucom KJW
        • Sauder KA.
        Benefits of participating with a partner in the National Diabetes Prevention Program.
        Diabetes Care. 2020; 43: e20-e21https://doi.org/10.2337/dc19-1489
        • Nhim K
        • Gruss SM
        • Porterfield DS
        • et al.
        Using a RE-AIM framework to identify promising practices in National Diabetes Prevention Program implementation.
        Implement Sci. 2019; 14: 81https://doi.org/10.1186/s13012-019-0928-9
        • Ritchie ND
        • Carroll JK
        • Holtrop JS
        • Havranek EP.
        Effects of physical activity goal attainment on engagement and outcomes in the National Diabetes Prevention Program.
        Transl Behav Med. 2018; 8: 932-937https://doi.org/10.1093/tbm/ibx021
        • Moin T.
        Should adults with prediabetes be prescribed metformin to prevent diabetes mellitus? Yes: high-quality evidence supports metformin use in persons at high risk.
        Am Fam Physician. 2019; 100 (https://www.aafp.org/afp/2019/0801/p134.html. Accessed January 23, 2022): 134-135